BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment

BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment

In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA (zanubrutinib). This marks the treatment as the first and only BTK inhibitor approved for adult patients in the U.S. who have undergone two or more lines […]

BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia

BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia

BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Brukinsa FDA approval is backed by the findings of two global phase 3 clinical trials wherein Brukinsa showed superior efficacy and […]